Predictive value of the antiangiogenic VEGF splice variant expression for bevacizumab efficacy in the phase III trial of bevacizumab and FOLFOX4 versus FOLFOX4 in previously treated patients with advanced colorectal cancer (ECOG E3200T2).
David O. Bates
Employment or Leadership Position - University of Bristol
Paul J. Catalano
No relevant relationships to disclose
Kirsty E. Symonds
No relevant relationships to disclose
Alexander H. R. Varey
No relevant relationships to disclose
Pramila Ramani
No relevant relationships to disclose
Peter James O'Dwyer
No relevant relationships to disclose
Bruce J. Giantonio
Honoraria - Roche/Genentech
Neal J. Meropol
Consultant or Advisory Role - AstraZeneca; Genentech; Genomic Health
Research Funding - Genomic Health
Al Bowen Benson
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Steven J. Harper
No relevant relationships to disclose